TY  - GEN
N2  - Immunotherapeutic approaches, aimed at modulating the immune system’s response to cancer and other diseases, have garnered increasing attention over the past decade. For some cancers such as melanoma, non-small cell lung cancer, and B-cell lymphomas, immunotherapy options have been transformative and some patients respond even in the most aggressive and refractory cases. Despite the optimism surrounding various immune-based approaches, many patients still don’t respond to treatment and the reasons why are poorly understood. The disparity in responses across patients and cancer types has highlighted a dire need for a better mechanistic understanding of the factors involved in therapeutic response to immunotherapies; supported by tools that help define which patients will benefit from these novel treatment options. While a variety of approaches exist in the immunotherapy space, some with systemic affects and others focused on specific immune targets, all approaches rely heavily on the adaptive immune system and response to class I antigens.
DO  - 10.6083/bpxhc42312
DO  - doi
AB  - Immunotherapeutic approaches, aimed at modulating the immune system’s response to cancer and other diseases, have garnered increasing attention over the past decade. For some cancers such as melanoma, non-small cell lung cancer, and B-cell lymphomas, immunotherapy options have been transformative and some patients respond even in the most aggressive and refractory cases. Despite the optimism surrounding various immune-based approaches, many patients still don’t respond to treatment and the reasons why are poorly understood. The disparity in responses across patients and cancer types has highlighted a dire need for a better mechanistic understanding of the factors involved in therapeutic response to immunotherapies; supported by tools that help define which patients will benefit from these novel treatment options. While a variety of approaches exist in the immunotherapy space, some with systemic affects and others focused on specific immune targets, all approaches rely heavily on the adaptive immune system and response to class I antigens.
T1  - Dynamics of antigen processing and presentation in the context of cancer
DA  - 2023-11-07
AU  - Weeder, Benjamin
L1  - https://digitalcollections.ohsu.edu/record/42312/files/Weeder.Benjamin.2023.pdf
PB  - Oregon Health and Science University
LA  - eng
PY  - 2023-11-07
ID  - 42312
L4  - https://digitalcollections.ohsu.edu/record/42312/files/Weeder.Benjamin.2023.pdf
KW  - Antigen Presentation
KW  - Immunotherapy
KW  - Prostatic Neoplasms
KW  - antigen processing
KW  - prostate cancer
KW  - pepsickle
TI  - Dynamics of antigen processing and presentation in the context of cancer
Y1  - 2023-11-07
L2  - https://digitalcollections.ohsu.edu/record/42312/files/Weeder.Benjamin.2023.pdf
LK  - https://digitalcollections.ohsu.edu/record/42312/files/Weeder.Benjamin.2023.pdf
UR  - https://digitalcollections.ohsu.edu/record/42312/files/Weeder.Benjamin.2023.pdf
ER  -